What is the evidence supporting ketamine treatment for post‑traumatic stress disorder (PTSD) in adults who have failed standard therapies?

Ketamine for PTSD: Emerging Evidence Shows Promise as Treatment Option

Ketamine shows preliminary but encouraging evidence for treating PTSD in adults who have failed standard therapies, though it is not currently recommended in major PTSD treatment guidelines and should be considered investigational. The most recent 2023 VA/DoD PTSD Clinical Practice Guideline does not include ketamine as a recommended treatment 1, while the 2022 VA/DoD guideline for Major Depressive Disorder supports ketamine only for treatment-resistant depression, not specifically for PTSD 2.

Current Guideline Position

The 2023 VA/DoD PTSD guideline makes no recommendation for or against ketamine for PTSD treatment 1. This represents a significant gap, as the guideline strongly recommends specific manualized psychotherapies (prolonged exposure, cognitive processing therapy, or EMDR) and certain medications (paroxetine, sertraline, or venlafaxine) as first-line treatments, but remains silent on ketamine.

Importantly, the guideline strongly recommends against benzodiazepines, cannabis, or cannabis-derived products for PTSD 1, establishing clear boundaries for what should not be used.

Research Evidence: What We Know

Rapid Symptom Reduction

The highest quality single study is a 2014 randomized, double-blind, crossover trial that demonstrated ketamine's rapid effects 3. In 41 patients with chronic PTSD:

• Single IV infusion of ketamine (0.5 mg/kg) produced significant PTSD symptom reduction within 24 hours compared to midazolam control
• Mean difference in Impact of Event Scale-Revised score was 12.7 points (95% CI, 2.5-22.8; P = .02)
• Benefits remained evident after adjusting for baseline depression severity
• Ketamine was well-tolerated without persistent dissociative symptoms
• Also reduced comorbid depressive symptoms

Recent Confirmatory Evidence

A 2025 double-blind randomized crossover study provides the most recent high-quality data 4:

• Intramuscular ketamine (0.5-1.0 mg/kg) versus fentanyl control in 33 treatment-resistant PTSD patients
• Ketamine at 1 mg/kg showed substantial IESR reductions, with effects persisting after 1 week
• Short-term dissociative and cardiovascular effects were manageable
• Conducted in community sample, enhancing generalizability

Real-World Effectiveness

A 2025 retrospective analysis of 8,136 PTSD patients (87% with comorbid depression) receiving ketamine IV therapy in outpatient settings showed 5:

• By the 6th treatment, mean PCL-5 reductions reached 22.4 points (exceeding clinically meaningful change threshold)
• Largest improvements occurred within first three treatments at doses of 0.6-0.8 mg/kg
• Higher doses in later treatments did not meaningfully enhance symptom reduction
• Logarithmic pattern suggests diminishing returns with additional treatments

Meta-Analytic Evidence

A 2024 meta-analysis found ketamine significantly improved PCL-5 scores at treatment endpoint (standardized effect size = 0.25; p=0.0363), though high heterogeneity was noted 6.

A 2026 individual participant data meta-analysis of 533 participants identified key predictors of response 7:

• Higher baseline PTSD severity was the most robust predictor of symptom reduction (β = 0.50 per PCL-5 point)
• More psychotherapy sessions associated with greater improvement (β = 1.03 per session)
• More ketamine sessions associated with benefit (β = 1.15 per session)
• Shorter treatment duration associated with better outcomes (β = -0.58 per week)

Practical Considerations

Dosing and Administration

Based on research evidence:

• IV ketamine: 0.5 mg/kg over 40 minutes is the most studied dose 3
• IM ketamine: 0.5-1.0 mg/kg, with 1.0 mg/kg showing superior effects 4
• Optimal response occurs within first 3 treatments at 0.6-0.8 mg/kg 5
• FDA labeling for anesthesia uses 1-4.5 mg/kg IV or 6.5-13 mg/kg IM 8, but PTSD studies use subanesthetic doses

Treatment Course

• Most substantial gains occur early in treatment (first 3 sessions) 5
• Effects may persist up to 1 week after single dose 4
• Combining with psychotherapy appears beneficial 7, 9
• Maintenance oral ketamine (1.5-2.5 mg/kg, 1-3 times weekly) sustained improvements over 6 weeks 10

Safety Profile

• Short-term dissociative effects are common but transient 4, 3
• Cardiovascular effects (elevated BP, HR) require monitoring 8
• No persistent dissociative symptoms reported in controlled trials 3
• Chronic use associated with genitourinary symptoms 8
• Emergency airway equipment must be immediately available 8

Critical Caveats

Limitations of Current Evidence

1. Most studies are small and of poor quality - the 2026 meta-analysis noted 9 of 12 studies were poor quality 7
2. High heterogeneity across studies limits confidence in pooled estimates 6
3. No long-term efficacy or safety data beyond weeks 2
4. Optimal dosing protocols remain unclear 11
5. Timing matters - perioperative ketamine may be protective, but immediate post-trauma administration may worsen dissociation 11

Contraindications and Warnings

Per FDA labeling 8:

• Contraindicated when blood pressure elevation would be hazardous
• Contraindicated with known hypersensitivity to ketamine
• Requires monitoring for hemodynamic instability
• Risk of respiratory depression with rapid administration
• Potential for drug interactions with sympathomimetics, benzodiazepines, opioids

Clinical Algorithm for Consideration

When to consider ketamine for PTSD:

1. Patient has failed evidence-based first-line treatments (trauma-focused psychotherapy AND at least 2 adequate trials of SSRIs/SNRIs per VA/DoD guidelines 1)
2. Severe, treatment-resistant symptoms with significant functional impairment
3. No contraindications (uncontrolled hypertension, cardiovascular disease, active substance use disorder, psychosis)
4. Ability to provide close monitoring during and after administration
5. Access to concurrent or adjunctive psychotherapy for optimal outcomes 7

Recommended approach if pursuing ketamine:

• Start with 0.5 mg/kg IV over 40 minutes or 1.0 mg/kg IM 4, 3
• Plan for 3-6 initial treatments over 2-3 weeks 5
• Combine with trauma-focused psychotherapy when possible 7
• Monitor cardiovascular parameters and dissociative symptoms
• Assess response after 3 treatments - if no meaningful improvement, reconsider continuation 5
• Consider maintenance dosing if initial response achieved 10

Bottom Line

Ketamine represents a promising but still investigational treatment for PTSD, particularly for patients who have exhausted standard evidence-based options. The evidence suggests rapid symptom reduction with effects most pronounced in the first few treatments, especially when combined with psychotherapy. However, the absence of ketamine from the 2023 VA/DoD PTSD guideline 1 and the predominance of poor-quality studies 7 means this should be considered an off-label, experimental approach requiring informed consent, close monitoring, and integration with established PTSD treatments. The most prudent approach is to exhaust guideline-recommended treatments first, then consider ketamine in specialized settings with appropriate monitoring and concurrent psychotherapy.